脂质体HLA—G抗肿瘤靶向药物的制备

The preparation of liposome HLA-G anti-tumor targeting drug

目的制备脂质体人白细胞抗原G（ human leukocyte antigen-G, HLA-G）抗肿瘤靶向药物，并对其形态、包封率和抗体效价等进行研究。方法采用薄膜分散法制备脂质体HLA—G抗肿瘤靶向药物。并用电子显微镜观察其外观形态；利用高效液相色谱测定该脂质体中游离紫杉醇的含量，计算包封率；采用ELISA测定HIA—G抗体效价和HLA-G抗体紫杉醇脂质体活性。结果制得的脂质体HLA—G抗肿瘤靶向药物的平均粒径为110．9nm，平均包封率为55％，合成的目的产物的抗体效价达到了未反应抗体效价的50％。结论制备的脂质体HLA—G抗肿瘤靶向药物相对分子质量适中、载药量较大、稳定性较好，但抗体效价较低，具有广泛的临床应用前景。

Objective To prepare the liposome human leukocyte antigen-G （HLA-G） anti-tumor targeting drug and study its morphology, entrapment efficiency and antibody titer. Methods Liposome HLA-G anti-tumor targeting drug was prepared by thin-film dispersion method and its morphology was observed by electron microscope. The content of free paclitaxel was determined by high-performance liquid chromatography and the entrapment efficiency of liposome HLA-G anti-tumor targeting drug was calculated. HLA-G antibody titer and activity of liposome HLA-G anti-tumor targeting drug were determined by ELISA. Results The average diameter and entrapment efficiency of liposome HLA-G anti-tumor targeting drug were 110.9 nm and 55%, respectively. Antibody titer of lipo-some HLA-G anti-tumor targeting drug was 50% of the level of unreaeted HLA-G antibody titer. Conclusion The liposome HLA-G anti-tumor targeting drug has moderate relative molecular mass, large drug loading, better stability, lower antibody titer,and broad clinical application prospects.